Choline Fuels Human Blood Stem Cell Stemness and Declines With Age and Leukemia
A landmark multi-omic study maps the full metabolic landscape of human bone marrow stem cells, revealing choline as a key stemness regulator.
Summary
Researchers at the Max Planck Institute and ETH Zürich performed the first comprehensive metabolome, lipidome, and transcriptome profiling of human bone marrow haematopoietic stem and progenitor cells (HSPCs). Using newly optimized low-input workflows requiring as few as 3,000–5,000 cells, they detected up to 193 metabolites and lipids across 86 human bone marrow samples. They found that choline levels are elevated in young healthy HSPCs compared to downstream progenitors, decline significantly with aging, and decrease even further in acute myeloid leukemia. Critically, supplementing HSPCs with choline enhanced lipid production and stemness properties, demonstrating choline's functional role in maintaining blood stem cell identity and pointing to a potential therapeutic lever for improving stem cell-based therapies.
Detailed Summary
Blood stem cells (haematopoietic stem cells, HSCs) sit at the apex of the blood-forming hierarchy and must balance quiescence with the lifelong ability to replenish all blood lineages. While genetic and transcriptomic studies have illuminated much about HSC biology, their metabolic landscape—especially in humans—has remained largely unmapped, hampered by the extreme rarity of these cells and the scarcity of human bone marrow samples.
This study addresses that gap head-on. The team developed and optimized two low-input analytical pipelines: targeted metabolomics for polar metabolites (requiring ~3,000 HSPCs) and a new untargeted lipidomics workflow (requiring ~5,000 HSPCs). Applied to 86 human bone marrow samples, these tools enabled detection of up to 193 metabolites and lipids from lineage⁻ CD34⁺ CD38⁻ HSPCs—the gold-standard phenotype for human HSPCs—and their downstream progenitors.
Key findings span three biological contexts. During differentiation, distinct metabolic signatures separate HSPCs from committed progenitors, with pathway-level changes in glycolysis, fatty acid oxidation, and lipid composition accompanying loss of stemness. With aging, HSPCs show progressive metabolic remodeling; most strikingly, choline levels—high in young healthy HSPCs—decline significantly in aged donors. In acute myeloid leukemia (AML), this choline decline is even more pronounced, suggesting choline depletion as a shared feature of both physiological aging and malignant transformation of the stem cell compartment.
Choline is an essential nutrient that feeds into phospholipid biosynthesis (notably phosphatidylcholine), one-carbon metabolism, and acetylcholine production. Functional follow-up experiments showed that exogenous choline supplementation boosts lipid production in HSPCs and enhances stemness markers, establishing a causal link. These data position choline not merely as a biomarker but as an active metabolic regulator of human HSC identity.
The study also integrates transcriptomic data, allowing metabolic findings to be anchored in gene expression changes, and provides an interactive online resource (cabezas-lab.shinyapps.io/HumanMetabolomics/) for the research community. Together, the dataset and analytical workflows constitute a foundational resource for human HSC metabolism research with clear implications for ex vivo stem cell expansion, transplantation biology, and leukemia treatment strategies.
Key Findings
- Choline is significantly elevated in young human HSPCs versus downstream progenitors and declines progressively with aging.
- Choline levels decrease even further in acute myeloid leukemia HSPCs, linking metabolic decline to malignancy.
- Choline supplementation boosts lipid biosynthesis and enhances stemness properties in human HSPCs.
- A new low-input lipidomics workflow detects up to 193 metabolites/lipids from as few as 3,000–5,000 human HSPCs.
- Integrated metabolome, lipidome, and transcriptome profiling across 86 BM samples reveals distinct metabolic signatures for differentiation, aging, and AML.
Methodology
The study used two low-input omics platforms—targeted polar metabolomics (~3,000 cells) and a newly optimized untargeted lipidomics workflow (~5,000 cells)—applied to 86 human bone marrow samples from young adults, aged donors, and AML patients. Data were integrated with transcriptomics, and results are publicly accessible via an interactive Shiny app.
Study Limitations
The study is primarily observational and cross-sectional; causal mechanisms by which choline depletion drives aging or AML phenotypes require further investigation. The low-input methods, while innovative, may introduce technical variability, and functional choline supplementation experiments were conducted ex vivo, leaving in vivo relevance to be confirmed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.